Targeting HIV Reservoirs & Working Towards a Cure

Targeting HIV reservoirs and working towards a cure requires a coordinated, multi-pronged strategy that acknowledges both the biology of latent infection and the clinical realities of safety and durability. The viral reservoir primarily long-lived, latently infected CD4⁺ T cells distributed across blood, lymphoid tissues, gut-associated lymphoid tissue and immune-privileged sites such as the central nervous system—persists despite antiretroviral therapy and is highly heterogeneous in cell phenotype and proviral integrity. Contemporary cure research therefore combines approaches to expose and eliminate or permanently silence these proviruses: latency-reversing agents (the “shock” in “shock-and-kill”) and immune effectors (therapeutic vaccines, broadly neutralizing antibodies, and engineered T cells) to clear reactivated cells; “block-and-lock” strategies to reinforce latency and prevent rebound; and precision genome-editing or targeted cytotoxic platforms to excise or destroy proviral DNA. Equally critical are advances in reservoir measurement, sensitive biomarkers of replication-competent virus, and careful combination regimens that maximize clearance while minimizing inflammation and off-target effects. Although significant scientific and translational hurdles remain—reservoir anatomical sanctuaries, clonal expansion of infected cells, and the risk of viral rebound the convergence of immunotherapy, molecular engineering and refined clinical trial design is steadily advancing realistic pathways toward durable remission and, ultimately, a functional or sterilizing cure.